Nature子刊：李晋/黄河/周璐/俞飚合作提出糖尿病治疗新策略，通过代谢重编程驱动β细胞新生

TL;DR - A Chinese multi-institution team (Fudan, Xinhua Hospital/SJTU, SIOC) reports in a Nature-family journal that metabolic reprogramming can convert pancreatic α cells into insulin-producing β-like cells and improve diabetes symptoms. Note: this is a wet-lab biology paper with no AI/ML component described.

• Loss of functional β cells defines diabetes; converting islet non-β cells (α cells) into insulin producers is a long-standing but clinically unrealized strategy.
• PRC2 inhibitors were found to promote β-cell-enriched gene expression in α cells by acting through the AR–ETV1 complex.
• AR inhibition suppressed glycogen synthesis and enhanced the pentose phosphate pathway (PPP).
• Directly supplying a PPP intermediate, methyl 6-phosphogluconate, reprogrammed α cells toward β-like identity, drove β cell neogenesis, and ameliorated diabetes in the reported models.
• Caveat: the post cites Nature Metabolism but the linked DOI (s41589-026-02293-z) corresponds to a different Nature journal; publication venue/date could not be verified from the content given.